CD7-targeted CAR-T

CD7-targeted CAR-T is a type of chimeric antigen receptor T-cell therapy engineered to recognize and eliminate cells expressing the **CD7 antigen**. CD7 is highly expressed on normal and malignant T cells, especially in T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL), as well as in certain peripheral T cell lymphomas (PTCLs). By harnessing a genetically modified T cell bearing a receptor that binds specifically to CD7, these therapies redirect cytotoxic T cell activity towards CD7+ cancer cells. Major challenges of this approach, such as fratricide (CAR-T cells attacking each other), have been addressed through methods like gene editing and expression blocking of CD7 on the therapeutic T cells themselves[1][5][7]. Several variations are in development, including products derived from autologous and allogeneic T cells and versions using nanoantibody-based CAR constructs. Clinical trials have demonstrated promising results, particularly in relapsed/refractory T-ALL, T-LBL, and PTCL, with substantial rates of complete remission and manageable levels of cytokine release syndrome and neurotoxicity[1][3][5]. The therapy is investigational and not yet FDA-approved.

Other names

CD7-specific CAR-TCD-7-specific CAR-TCD 7-specific CAR-Tanti-CD7 CAR-T cellanti-CD-7 CAR-T cellanti-CD 7 CAR-T cellCD7 CAR T-cellCD-7 CAR T-cellCD 7 CAR T-cellCD7 chimeric antigen receptor T cellCD-7 chimeric antigen receptor T cellCD 7 chimeric antigen receptor T cell